TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Intensity Therapeutics, Inc. ( (INTS) ) is now available.
On September 10, 2025, Intensity Therapeutics, Inc. provided an update on its INVINCIBLE-4 study, revealing a pathological complete response in the first evaluated patient of Cohort A. Despite a favorable safety profile, localized skin irritation led to a pause in new patient enrollment to assess data and make necessary adjustments.
The most recent analyst rating on (INTS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cancer immunotherapy treatments.
Average Trading Volume: 4,432,898
Technical Sentiment Signal: Sell
Learn more about INTS stock on TipRanks’ Stock Analysis page.